{
  "treatment_regimens": [
    "pembrolizumab alone (IO-mono)",
    "pembrolizumab in combination with platinum-based chemotherapy (CT-IO)"
  ],
  "countries": [
    "France"
  ],
  "populations": [
    {
      "stage, histology": "Stage III (not amenable to curative treatment) or Stage IV, non-squamous NSCLC",
      "pdl1_status": "PD-L1 \u2265 50%",
      "n": 243
    },
    {
      "stage, histology": "Stage IV, non-squamous NSCLC",
      "pdl1_status": "PD-L1 \u2265 90%",
      "n": 59
    },
    {
      "stage, histology": "Stage IV, non-squamous NSCLC",
      "pdl1_status": "PD-L1 50-89%",
      "n": 82
    },
    {
      "stage, histology": "Locally advanced, non-squamous NSCLC",
      "pdl1_status": "PD-L1 \u2265 50%",
      "n": 26
    },
    {
      "stage, histology": "Metastatic, non-squamous NSCLC",
      "pdl1_status": "PD-L1 \u2265 50%",
      "n": 115
    }
  ],
  "results": {
    "pembrolizumab alone (IO-mono)": {
      "median_os": "not reached",
      "os_12_month": "66.1%",
      "median_rw_pfs": "10.6 months"
    },
    "pembrolizumab in combination with platinum-based chemotherapy (CT-IO)": {
      "median_os": "not reached",
      "os_12_month": "70.2%",
      "median_rw_pfs": "11.3 months"
    },
    "group_difference": "no difference was observed between groups (p=0.51)"
  },
  "study_name": "Study from Pons-Tostivint 2023.pdf",
  "file_name": "Pons-Tostivint 2023.pdf"
}